Tolerability And Pharmacokinetic Profile Of RV568, A Narrow Spectrum Kinase Inhibitor, Following Single And Repeat Inhaled Dosing In Healthy Volunteers
Latest Information Update: 29 May 2013
At a glance
- Drugs RV 568 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Pharmacokinetics
- 29 May 2013 New trial record
- 22 May 2013 Results (cohort 3) presented at the 109th International Conference of the American Thoracic Society.
- 22 May 2013 Results (cohort 2) presented at the 109th International Conference of the American Thoracic Society.